Dermatology · Riverside, CA
NPI
1407923311
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
10800 Magnolia Ave
Riverside, CA, 92505
Phone (909) 353-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$517
33 services
Medicare patients, 2024
17
Average age 66
Drug cost, 2024
$255K
2,518 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Selim M Inel prescribed most often to Medicare patients was Triamcinolone Acetonide, with 289 prescriptions and refills. In total Selim M Inel wrote 2,518 Medicare prescriptions that cost $255K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-11-29.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Triamcinolone Acetonide Generic | 289 | 415 | 173 | $9,795 |
| Fluocinonide Generic | 243 | 258 | 114 | $5,008 |
| Clobetasol Propionate Generic | 226 | 254 | 81 | $5,454 |
| Ketoconazole Generic | 207 | 215 | 86 | $3,044 |
| Fluorouracil Generic | 179 | 179 | 138 | $6,701 |
| Hydrocortisone Generic | 176 | 202 | 82 | $3,201 |
| Betamethasone Diprop Augmented Betamethasone/Propylene Glyc | 154 | 190 | 56 | $8,259 |
| Tacrolimus Generic | 148 | 172 | 69 | $17K |
| Metronidazole Generic | 122 | 126 | 46 | $2,041 |
| Retin-A Tretinoin | 93 | 100 | 29 | $2,694 |
| Doxycycline Monohydrate Generic | 91 | 226 | 44 | $4,589 |
| Calcipotriene Generic | 83 | 96 | 27 | $12K |
| Clindamycin Phosphate Generic | 66 | 71 | 29 | $1,648 |
| Ciclopirox Generic | 66 | 66 | 28 | $1,141 |
| Vectical Calcitriol | 49 | 74 | 22 | $11K |
Brand drugs: 226 claims; generic drugs: 2,292 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Selim M Inel were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.